Percutaneous Coronary Intervention News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Reporting outcomes of PCI may not improve care
(Reuters Health) - Public reporting of outcomes for percutaneous coronary intervention (PCI) was supposed to improve quality, but some doctors say it hasn't delivered on the goal of enhancing patient care. (Source: Reuters: Health)
Source: Reuters: Health - May 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Doctors May Avoid Performing PCI Due to Public Reporting
WEDNESDAY, May 16, 2018 -- Current percutaneous coronary intervention (PCI) public reporting programs could have negative effects, with physicians avoiding PCI in high-risk patients, according to a study published online May 9 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 16, 2018 Category: Pharmaceuticals Source Type: news

How do public 'report cards' affect physicians' treatment decisions?
(Beth Israel Deaconess Medical Center) Researchers from the Smith Center for Outcomes Research in Cardiology at Beth Israel Deaconess Medical Center (BIDMC) provide a closer look at physicians' knowledge, attitudes and beliefs about public reporting on percutaneous coronary intervention (PCI). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 10, 2018 Category: International Medicine & Public Health Source Type: news

Zoll Medical leads debt round for TherOx
TherOx said today it completed a new round of debt financing led by Asahi Kasei (TYO:3407) subsidiary Zoll Medical for an undisclosed amount. Funds from the deal will be used to support the US market introduction and commercialization of the Irvine, Calif.-based company’s SuperSaturated Oxygen Therapy system designed to treat patients with acute myocardial infarction once the system wins FDA premarket approval. TherOx said that it also recently released results from a study of its SSO2 Therapy system which confirmed the safety and effectiveness of the device in the treatment of anterior acute myocardial infarction...
Source: Mass Device - May 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Asahi Kasei Corp. TherOx Inc Zoll Medical Corp. Source Type: news

Timely Receipt of PCI in STEMI Up With Hospital Bypass Policy
TUESDAY, May 1, 2018 -- Adoption of policies allowing emergency medical services (EMS) to bypass non-percutaneous coronary intervention (PCI) capable hospitals for patients with ST-segment elevation myocardial infarction (STEMI) is associated with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

SCAI updates consensus on length of stay for percutaneous coronary intervention
(Society for Cardiovascular Angiography and Interventions) Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary intervention (PCI) will allow for flexibility in length of stay while ensuring patient safety. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2018 Category: International Medicine & Public Health Source Type: news

Heavy US Burden of 30-Day Readmissions After PCI Heavy US Burden of 30-Day Readmissions After PCI
Almost 1 in 10 Americans undergoing percutaneous coronary intervention return with an unplanned readmission within 30 days, despite advances in the technology.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Abbot launches study comparing OCT to angiography in stent placement procedures
Abbott (NYSE:ABT) today announced the launch of new trial exploring long-term outcomes in patients who underwent stent implantation guided by optical coherence tomography as compared to angiography. The first patient in the trial was enrolled by Dr. Franco Fabbiocchi at Milan, Italy’s IRCCS Centro Cardiologico, the Abbot Park, Ill.-based company said. “Today, most of the world uses angiography for stent implantation using a two-dimensional view of the coronary artery to assess a complex three-dimensional structure. Physicians need new technology to help optimize percutaneous coronary intervention, and OCT prov...
Source: Mass Device - April 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Imaging Abbott Source Type: news

Abbott launches study comparing OCT to angiography in stent placement procedures
Abbott (NYSE:ABT) today announced the launch of new trial exploring long-term outcomes in patients who underwent stent implantation guided by optical coherence tomography as compared to angiography. The first patient in the trial was enrolled by Dr. Franco Fabbiocchi at Milan, Italy’s IRCCS Centro Cardiologico, the Abbot Park, Ill.-based company said. “Today, most of the world uses angiography for stent implantation using a two-dimensional view of the coronary artery to assess a complex three-dimensional structure. Physicians need new technology to help optimize percutaneous coronary intervention, and OCT prov...
Source: Mass Device - April 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Imaging Abbott Source Type: news

Better PCI Outcomes With Genotype-guided Antiplatelet Therapy Better PCI Outcomes With Genotype-guided Antiplatelet Therapy
The use of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI) is associated with better clinical outcomes, according to a new study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 10, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Abiomed Earns FDA Approval for Adding Optical Sensor to Impella CP Heart Pump
Abiomed, which had a busy 2017 and was among our Company of the Year finalists, reported today that it has received FDA premarket approval (PMA) for its Impella CP heart pump with SmartAssist, utilizing an optical sensor. The sensor is one component of the SmartAssist technology, which also includes a software update enabling informational displays of left ventricular pressure (LVP), end-diastolic pressure (EDP), and cardiac power output (CPO) data on the Impella Console, an Abiomed spokesperson told MD+DI. The Impella CP heart pump had already earned FDA approval for treating patients in cardiogenic shock as well as patie...
Source: MDDI - April 2, 2018 Category: Medical Devices Authors: Daphne Allen Tags: Cardiovascular Source Type: news

FDA clears robotic movement software from Corindus
The FDA granted 510(k) clearance to the first automated robotic movement software designed for Corindus Vascular Robotics (OTC:CVRS) CorPath GRX percutaneous coronary intervention platform, the company reported today. The Rotate on Retract feature allows the person operating the CorPath GRX to navigate to a targeted lesion by automatically turning the guidewire upon joystick retraction. The software also won CE Mark approval in the European Union earlier this year. Today, Dr. Nelson Bernado, the medical director of MedStar Heart Institute’s Peripheral Vascular Laboratory, is slated to perform a robotic-assited perip...
Source: Mass Device - March 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Regulatory/Compliance Robotics Software / IT Vascular Corindus Vascular Robotics Source Type: news

ACC, Saudi Arabian Cardiac Interventional Society partner on registries
(American College of Cardiology) The American College of Cardiology and the Saudi Arabian Cardiac Interventional Society have partnered to implement the National Cardiovascular Data Registry's (NCDR) CathPCI Registry in hospitals across Saudi Arabia. The CathPCI Registry assesses the characteristics, treatments and outcomes of heart disease patients who receive diagnostic catheterization as well as percutaneous coronary intervention procedures. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 27, 2018 Category: International Medicine & Public Health Source Type: news

Abiomed wins expanded Impella FDA nod for elective, urgent high-risk PCI
Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval for its Impella 2.5 and Impella CP heart pumps, now cleared for use during elective and urgent high risk percutaneous coronary intervention procedures. With the expansion, the Impella heart pump is cleared for use with patients with severe coronary artery disease, complex anatomy and a number of co-morbidities with or without depressed ejection fractions, the Danvers, Mass.-based company said. “This expanded FDA approval with moderately reduced ejection fraction validates our real-world experience using hemodynamic support in patients turned down ...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Catheters Food & Drug Administration (FDA) Regulatory/Compliance Abiomed Source Type: news

Shorter time between first medical contact to PCI in heart patients linked to saving lives
(European Society of Cardiology) Heart experts are calling for immediate action following new research in the European Heart Journal that shows every minute counts for patients who suffer the most severe type of heart attack. The study shows numbers of deaths rise steadily and rapidly the longer the time between patients' first contact with a medical professional and when they are treated in hospital with percutaneous coronary intervention (PCI) to insert a balloon catheter to widen blocked arteries and restore blood flow to the heart. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 13, 2018 Category: International Medicine & Public Health Source Type: news